GlycoZym has a broad patent portfolio (see patents) and actively seeks out-licensing opportunities and partnerships for its technologies and medical applications.
GlycoZym has issued patents on a number of the key enzymes and genes controlling the O-glycosylation of proteins. Applications include enzymatic synthesis, engineering of host production cells, and antibodies.
GlycoZym has patent applications pending on its PTM-peptide biomarker discovery platform and validated biomarkers.
GlycoZym has issued patents and pending applications on innovative adjuvant strategies and cancer vaccine targets.
GlycoZym has issued patents on drug targets for alleviating mucin accumulation in respiratory diseases such as Chronic Obstructive Lung Disease (COPD).
GlycoZym has unique monoclonal antibodies to aberrant glycans found in cancer, and a simple platform for the generation of disease-specific monoclonal antibodies to PTM-peptide epitopes.